Many thanks to Dr. David Juurlink and Dr. Walter Himmel for their expert contributions to the EM Cases podcast that inspired this article.

Dr. Helman is an emergency physician at North York General Hospital in Toronto. He is an assistant professor at the University of Toronto, Division of Emergency Medicine, and the education innovation lead at the Schwartz/Reisman Emergency Medicine Institute. He is the founder and host of Emergency Medicine Cases podcast and website.

References

1. Hohl CM, Robitaille C, Lord V, et al. Emergency physician recognition of adverse drug-related events in elder patients presenting to an emergency department. Acad Emerg Med. 2005;12:197-205.
2. Hohl CM, Zed PJ, Brubacher JR, et al. Do emergency physicians attribute drug-related emergency department visits to medication-related problems? Ann Emerg Med. 2010;55:493-502.
3. Classen D, Pestotnik S, Evans S, et al. Adverse drug events in hospitalized patients. JAMA. 1997;277:301-6.
4. Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563-9.
5. Rosas-Carrasco O, García-Peña C, Sánchez-García S, et al. The relationship between potential drug-drug interactions and mortality rate of elderly hospitalized patients. Rev Invest Clin. 2011;63(6):564-73.
6. Chang TI, Park H, Kim DW, et al. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10(1):18964.
7. Pretorius RW, Gataric G, Swedlund SK, et al. Reducing the risk of adverse drug events in older adults. Am Fam Physician. 2013;87(5):331-6.
8. Hohl CM, Badke K, Zhao A, et al. Prospective validation of clinical criteria to identify emergency department patients at high risk for adverse drug events. Acad Emerg Med. 2018;25(9):1015-26.
9. Wolff J, Hefner G, Normann C, et al. Predicting the risk of drug-drug interactions in psychiatric hospitals: a retrospective longitudinal pharmaco-vigilance study. BMJ Open. 2021;11(4):e045276.
10. Mendu ML, Waikar SS. Drug-drug interactions and acute kidney injury: caveat prescriptor. Am J Kidney Dis. 2014;64(4):492-4.
11. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging. 1995;7(1):10-8.
12. Visser LE, Graatsma HH, Stricker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol. 2002;53(2):183-8.
13. Wongrakpanich S, Wongrakpanich A, Melhado K, et al. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143-150.
14. Boon M, van Dorp E, Broens S, et al. Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events. Ann Palliat Med. 2020;9(2):542-557.
15. Talton CW. Serotonin syndrome/serotonin toxicity. Fed Pract. 2020;37(10):452-459.
16. Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med. 2010;38(4):477-80.
17. Kyotani Y, Zhao J, Nakahira K, et al. The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome. Sci Rep. 2023;13(1):18459.
18. Meid AD, Bighelli I, Mächler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264
19. Nachimuthu S, Assar MD, Schussler JM. Druginduced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241-53.
20. Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ. 2015;187(4):E138-E143.
21. Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical pharmacokinetics in kidney disease: Fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085-95.
22. Clark NP, Delate T, Riggs CS, et al. Warfarin interactions with antibiotics in the ambulatory care setting. JAMA Intern Med. 2014;174(3):409-16.
23. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170(12):1045-9.
24. Abu Mellal A, Hussain N, Said AS. The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies. Ther Clin Risk Manag. 2019;15:921-36.
25. Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ. 2011;183(3):303-7.
26. Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805-14.
27. Dharmarajan L, Sajjad W. Potentially lethal acetaminophen-warfarin interaction in an older adult: an under-recognized phenomenon? J Am Med Dir Assoc. 2007;8(8):545-7.
28. Paulison B, Léos CL. Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. Cardiovasc Toxicol. 2010;10(4):306-10.
29. Mills GA, Horn JR. Beta-blockers and glucose control. Drug Intell Clin Pharm. 1985;19(4):246-51.